For example, although we see some evidence for a protective effect against IBD of chronically raised levels of MCP‐1, the increase in MCP‐1 levels that reflect the inflammatory response to increased adiposity are unlikely to have the same downstream consequences. This evidence concerns the gene CCL2 and inflammatory bowel disease.